Janet L. Lensing

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

Amita Patnaik, Paul Haluska, Anthony W. Tolcher et al. · Clinical Cancer Research · 2015 · 138 citations

Medicine, Oncology, Pharmacology +14

Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points

Keith C. Bible, Janet L. Lensing, Sacha A. Nelson et al. · Clinical Cancer Research · 2005 · 64 citations

Medicine, Oncology, Pharmacology +17

A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors

Andrea E. Wahner Hendrickson, Michael E. Menefee, Lynn C. Hartmann et al. · Clinical Cancer Research · 2017 · 57 citations · Full text

Medicine, Oncology, Pharmacology +15

A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM)

Heather A. Wakelee, Alex A. Adjei, Joanne Halsey et al. · Journal of Clinical Oncology · 2006 · 23 citations

Medicine, Oncology, Pharmacology +16

A phase I study of XL647, an EGFR, HER2, VEGFR2 inhibitor, administered orally daily to patients (pts) with advanced solid malignancies (ASM)

Heather A. Wakelee, J. M. Fehling, Julian R. Molina et al. · Journal of Clinical Oncology · 2008 · 12 citations

Medicine, Oncology, Pharmacology +17